Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Last Updated: May 26, 2022

STALEVO 50 Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

When do Stalevo 50 patents expire, and what generic alternatives are available?

Stalevo 50 is a drug marketed by Orion Pharma and is included in one NDA.

The generic ingredient in STALEVO 50 is carbidopa; entacapone; levodopa. There are eighteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the carbidopa; entacapone; levodopa profile page.

Drug patent expirations by year for STALEVO 50
Recent Clinical Trials for STALEVO 50

Identify potential brand extensions & 505(b)(2) entrants

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityPhase 4
Asan Medical CenterN/A
SynAgile CorporationPhase 2

See all STALEVO 50 clinical trials

US Patents and Regulatory Information for STALEVO 50

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Orion Pharma STALEVO 50 carbidopa; entacapone; levodopa TABLET;ORAL 021485-001 Jun 11, 2003 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for STALEVO 50

International Patents for STALEVO 50

See the table below for patents covering STALEVO 50 around the world.

Country Patent Number Title Estimated Expiration
German Democratic Republic 281375 VERFAHREN ZUR HERSTELLUNG VON BRENZKATECHIN-DERIVATEN See Plans and Pricing
Austria A312987 See Plans and Pricing
Netherlands 194821 See Plans and Pricing
Norway 20110090 See Plans and Pricing
Yugoslavia 47790 See Plans and Pricing
Iceland 1753 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for STALEVO 50

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0426468 0490007-2 Sweden See Plans and Pricing PRODUCT NAME: (E)-2-CYANO-N,N-DIETYL-3-(3,4-DIHYDROXI-5-NITROFENYL)AKRYLAMID; REGSISTRATION NO/DATE: EU/1/03/260/001 20031017
0426468 91071 Luxembourg See Plans and Pricing 91071, EXPIRES: 20151101
0426468 C00426468/01 Switzerland See Plans and Pricing FORMER REPRESENTATIVE: BOHEST AG, CH
0426468 CA 2004 00007 Denmark See Plans and Pricing
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:


Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.